Literature DB >> 18941930

Expression of ER, Ki-67 and cylinD1 in the pre-cancerous breast of Chinese patients.

Cheng-Jun Zhou1, Qing-Hui Zhang, Ting-Guo Zhang, Shan-Zhen Sun, Hong Li, Yan Wang, Zhi-Yan Liu.   

Abstract

To investigate the expression and association of ER, Ki-67 and cyclinD1 in usual ductal hyperplasia(UDH), atypical ductal hyperplasia (ADH) and ductal carcinoma in situ(DCIS) in the breast. The study included 56 cases of pre-cancerous lesions which were surgically excised at Qi Lu Hospital of Shangdong University. Immunohistochemistry was used to determine the expression of ER, Ki-67 and cyclinD1 and double-labelling immunofluorescence technique was used to observe the coexpression of ER and Ki-67. The expression and distribution of ER-positive cells were significantly different in UDH, ADH and DCIS. The ER-positive cells were much more in UDH than in normal TDLUs (terminal duct lobular units). The distribution of ER-positive cells interspersed amid ER-negative cells within UDH. However , the ER positive cells showed marked increases in ADH and low grade nuclear DCIS (P < 0.05), distributing in almost all constituent cells. The expression of ki-67 and cyclinD1 were significantly different between UDH and DCIS (P < 0.05) , and a positive correlation was found between expression of Ki-67 and morphological classification of pre-cancerous lesions (r = 0.3522, P < 0.05) as well as cyclinD1 (r = 0.3901, P < 0.05). Double-labelling immunofluorescence showed that there was no coexpression of ER and Ki-67 in normal breast tissue. The coexpression of the two markers was found in ADH and increased in DCIS. Overexpression of ER, Ki-67 and cyclinD1 significantly accompanies the transition of normal cells and UDH to ADH and DCIS. The coexpression of ER and ki-67 may present the early change in carcinogenesis of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941930     DOI: 10.1007/s12253-008-9100-6

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  16 in total

1.  Subgroups of non-atypical hyperplasia of breast defined by proliferation of oestrogen receptor-positive cells.

Authors:  M Iqbal; M P Davies; B S Shoker; C Jarvis; D R Sibson; J P Sloane
Journal:  J Pathol       Date:  2001-03       Impact factor: 7.996

2.  Estrogen receptor-positive proliferating cells in the normal and precancerous breast.

Authors:  B S Shoker; C Jarvis; R B Clarke; E Anderson; J Hewlett; M P Davies; D R Sibson; J P Sloane
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Estrogen and progesterone receptors in the normal female breast.

Authors:  D Ricketts; L Turnbull; G Ryall; R Bakhshi; N S Rawson; J C Gazet; C Nolan; R C Coombes
Journal:  Cancer Res       Date:  1991-04-01       Impact factor: 12.701

4.  The effect of an estrone D-lactam steroid ester derivative on breast cancer cells and its predicted binding interactions with the ligand binding domain of estrogen receptor-alpha.

Authors:  Michael Kontos; Marilena Nikolopoulou; Dimitrios T P Trafalis; George D Geromichalos; Catherine Koukoulitsa; J Charalambos Camoutsis; Elias Bastounis; Panayiotis Karamanakos
Journal:  Oncol Res       Date:  2005       Impact factor: 5.574

Review 5.  Role of hormones in mammary cancer initiation and progression.

Authors:  I H Russo; J Russo
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

6.  Oestrogen receptor expression in the normal and pre-cancerous breast.

Authors:  B S Shoker; C Jarvis; D R Sibson; C Walker; J P Sloane
Journal:  J Pathol       Date:  1999-07       Impact factor: 7.996

7.  A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.

Authors:  S A Fuqua; C Wiltschke; Q X Zhang; A Borg; C G Castles; W E Friedrichs; T Hopp; S Hilsenbeck; S Mohsin; P O'Connell; D C Allred
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

8.  Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study.

Authors:  D D Giri; S A Dundas; J F Nottingham; J C Underwood
Journal:  Histopathology       Date:  1989-12       Impact factor: 5.087

9.  Estrogen receptor values in patients with benign breast disease.

Authors:  J C Allegra; M E Lippman; L Green; A Barlock; R Simon; E B Thompson; K K Huff; W Griffin
Journal:  Cancer       Date:  1979-07       Impact factor: 6.860

10.  Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.

Authors:  Hyman B Muss; Janice Yanushka Bunn; Abigail Crocker; Karen Plaut; James Koh; Nick Heintz; Mercedes Rincon; Donald L Weaver; Diane Tam; Barbara Beatty; Peter Kaufman; Michael Donovan; David Verbel; Linda Weiss
Journal:  Breast J       Date:  2007 Jul-Aug       Impact factor: 2.431

View more
  5 in total

Review 1.  A review of prognostic and predictive biomarkers in breast cancer.

Authors:  Elaheh Tarighati; Hadi Keivan; Hojjat Mahani
Journal:  Clin Exp Med       Date:  2022-01-15       Impact factor: 3.984

2.  fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions.

Authors:  Maria Soares; Assunção N Correia; Mariana R Batista; Jorge Correia; Fernando Ferreira
Journal:  Animals (Basel)       Date:  2022-06-21       Impact factor: 3.231

Review 3.  Biomarkers in triple negative breast cancer: A review.

Authors:  Budhi S Yadav; Priyanka Chanana; Swaty Jhamb
Journal:  World J Clin Oncol       Date:  2015-12-10

4.  Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.

Authors:  Sara A Lari; Henry M Kuerer
Journal:  J Cancer       Date:  2011-05-01       Impact factor: 4.207

5.  Association of Over-Expressed Estrogen Receptor Alpha with Development of Tamoxifen Resistant Hyperplasia and Adenocarcinomas in Genetically Engineered Mice.

Authors:  Anne M Miermont; Marina Carla Cabrera; Silvina M Frech; Rebecca E Nakles; Edgar S Diaz-Cruz; Maddalena Tilli Shiffert; Priscilla A Furth
Journal:  Anat Physiol       Date:  2012-06-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.